EVALUATION OF A VISUAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR PREGNANCY DETECTION IN FOUR UNGULATE SPECIES

VALIDATION OF A NOVEL ENZYME-LINKED IMMUNOSORBENT ASSAY FOR DETECTING PREGNANCY-SPECIFIC PROTEIN B IN MASAI GIRAFFE (GIRAFFA CAMELOPARDALIS TIPPELSKIRCHI)

The Masai giraffe (Giraffa camelopardalis tippelskirchi) is endangered in the wild, and successful reproduction in managed care is important to help maintain assurance populations of this highly charismatic subspecies. Detection of pregnancy in giraffes using hormonal monitoring requires multiple samples and cannot distinguish pregnancy from pseudopregnancy. A novel enzyme-linked immunosorbent assay that can detect pregnancy-specific protein B (PSPB) for pregnancy diagnosis with a single serum sample was developed from a reticulated giraffe (Giraffa camelopardalis reticulata) placenta. Seventy-eight serum samples were analyzed from three female Masai giraffes before and during five gestation periods that resulted in live calf births. Using an optical density cutoff of 0.2, the assay showed a sensitivity of 93% and specificity of 100% for all samples tested. At 59 d of gestation, sensitivity increased to 100%. The earliest pregnancy detection was at 40 d of gestation. This study documents the successful development of a blood-based PSPB assay for pregnancy diagnosis in Masai giraffe, which can help advance conservation efforts in this endangered species.

Label-Free Quantification (LFQ) of Fecal Proteins for Potential Pregnancy Detection in Polar Bears

Reliable pregnancy diagnostics would be beneficial for monitoring polar bear (Ursus maritimus) populations both in situ and ex situ, but currently there is no method of non-invasive pregnancy detection in this species. Recent reports in several carnivore species described the identification of fecal proteins that may serve as pregnancy biomarkers; however, repeatability has been limited. The objective of the current analysis was to utilize an unbiased, antibody-free, label-free method for the identification and quantification of fecal proteins to determine if differences associated with pregnancy are detectable in polar bears. Protein was extracted from fecal samples (n = 48) obtained from parturient (n = 6) and non-parturient (n = 6) profiles each at four timepoints: pre-breeding season, embryonic diapause, early placental pregnancy, and mid-placental pregnancy. Protein was prepared and analyzed on the Thermo Orbitrap Eclipse nanoLC-MS/MS system. A total of 312 proteins was identified and quantified; however, coefficients of variation (CV) were high for both abundance ratio variability (384.8 ± 61.0% SEM) and within group variability (86.8 ± 1.5%). Results of this study suggest that the inconsistencies in specific protein concentrations revealed previously by antibody-based assays may not be due to that methodology’s limitations, but rather, are reflective of true variation that exists among samples.

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease

This study mainly analyzes the clinical effect of glucocorticoid (GC) plus intravenous immunoglobulin (IVIG) in treating children with immunoglobulin (Ig)-insensitive Kawasaki disease (KD). From September 2013 to November 2021, 86 Ig-insensitive KD children were selected, including 46 children (observation group, Obs) treated with GC plus IVIG, and 40 children (control group, Con) treated with IVIG. The symptom (fever and fever) resolution time, inflammatory factors (C-reactive protein, CRP; procalcitonin, PCT; interleukin-6, IL-6), immune indicators (CD3+, CD4+, CD8+ T lymphocytes CD3+, CD4+, and CD4+/CD8+), and incidence of adverse reactions were compared between the groups. The results identified shorter fever and rash resolution time in Obs compared with Con. The posttreatment CRP, PCT, IL-6, and CD8+ and the incidence of adverse events reduced notably in Obs and were lower than Con, while CD3+, CD4+, and CD4+/CD8+ elevated statistically and were higher than that of Con. Our results indicate that GC plus IVIG can significantly promote symptom resolution, alleviate inflammatory response, and improve immune function in children with Ig-insensitivity KD, with favorable safety and clinical promotion value.